Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Other
Ratios

Theravance Biopharma (TBPH) Receivables - Other (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Receivables - Other for 13 consecutive years, with $18.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Receivables - Other rose 8.44% to $18.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $18.3 million, a 8.44% increase, with the full-year FY2024 number at $18.4 million, changed N/A from a year prior.
  • Receivables - Other was $18.3 million for Q3 2025 at Theravance Biopharma, down from $21.9 million in the prior quarter.
  • In the past five years, Receivables - Other ranged from a high of $43.8 million in Q3 2021 to a low of $12.3 million in Q1 2023.
  • A 5-year average of $21.0 million and a median of $16.8 million in 2024 define the central range for Receivables - Other.
  • Peak YoY movement for Receivables - Other: soared 253.04% in 2021, then crashed 67.76% in 2022.
  • Theravance Biopharma's Receivables - Other stood at $43.8 million in 2021, then plummeted by 61.65% to $16.8 million in 2022, then rose by 1.62% to $17.1 million in 2023, then rose by 8.11% to $18.4 million in 2024, then decreased by 0.94% to $18.3 million in 2025.
  • Per Business Quant, the three most recent readings for TBPH's Receivables - Other are $18.3 million (Q3 2025), $21.9 million (Q2 2025), and $15.4 million (Q1 2025).